News & Events

Press Releases

July 12, 2021
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

June 22, 2021
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors

May 17, 2021
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board

May 5, 2021
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors

March 8, 2021
Caribou Biosciences to Participate in Three Upcoming Investor Conferences in March

March 3, 2021
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

view all press releases

Upcoming Events

There are no upcoming events at this time.

In the News

April 15, 2021
CRISPR treating cancer, Rachel Haurwitz, Co-founder and CEO, Caribou Biosciences

February 23, 2021
Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products